Kolexia
Grenier Julien Oncologie médicale
Grenier Julien
Oncologie médicale
Institut Sainte Catherine
Avignon, France
110 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Neutropénie Tumeurs du sein triple-négatives Tumeurs de l'ovaire Métastase tumorale Neuropathies périphériques Lymphopénie Nausée Tumeurs des voies biliaires

Collaborateurs

Voir plus
Arnaud Antoine
Arnaud Antoine
Imag En Coupes Avig Vaucl Site Ste Cat, Avignon, France
Mege Alice
Mege Alice
Imag En Coupes Avig Vaucl Site Ste Cat, Avignon, France
De Rauglaudre Gaetan
De Rauglaudre Gaetan
Imag En Coupes Avig Vaucl Site Ste Cat, Avignon, France
Darmon Jean-Claude
Darmon Jean-Claude
Polyclinique Urbain V, Avignon, France

Industries

Voir plus
B3TSI
12 collaboration(s)
Dernière en 2023
AstraZeneca
8 collaboration(s)
Dernière en 2023
MSD
5 collaboration(s)
Dernière en 2022
Axess Research
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
TUC-TOC: Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II
Essai Clinique (Seagen)   07 mars 2024
CUPCAKE: Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Essai Clinique (Institut Curie)   06 mars 2024
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
Withdrawal notice to « Patients sous Palbociclib et hormonothérapie pour un cancer du sein métastatique : peut-on prédire la survenue d’une hématotoxicité précoce et sévère ? » Bull Cancer 108 (2021) 544–552 https://doi.org/10.1016/j.bulcan.2021.01.007.
Bulletin du cancer   20 janvier 2024
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
Ineffective Erythropoiesis Negatively Impacts the Erythroblastic Island in Sickle Cell Disease
65th ASH Annual Meeting Abstracts   02 novembre 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA oncology   19 octobre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023